ATOS - Atossa Genetics Stock Price, News & Analysis

$0.36 0.00 (0.00 %)
(As of 11/24/2017 04:37 AM ET)
Previous Close$0.36
Today's Range$0.35 - $0.38
52-Week Range$0.31 - $2.60
Volume689,000 shs
Average Volume1.36 million shs
Market Capitalization$9.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37

About Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics logoAtossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.


Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATOS
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.76%
Quick Ratio2.76%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book3.60

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($2.35)
Net Income$-6,360,000.00
Net MarginsN/A
Return on Equity-313.22%
Return on Assets-211.43%

Miscellaneous

Employees6
Outstanding Shares26,520,000

Frequently Asked Questions for Atossa Genetics (NASDAQ:ATOS)

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc. (NASDAQ:ATOS) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.20. View Atossa Genetics' Earnings History.

When will Atossa Genetics make its next earnings announcement?

Atossa Genetics is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Atossa Genetics.

Who are some of Atossa Genetics' key competitors?

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the folowing people:

  • Steven C. Quay M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Kyle Guse Esq., CPA, Chief Financial Officer, General Counsel, Secretary (Age 51)
  • Cindy Atha, Vice President of Sales and Marketing
  • Janet Rose Rea MSPH, Vice President - Regulatory Affairs and Quality
  • Shu-Chih Chen Ph.D., Director (Age 53)
  • Stephen J. Galli M.D., Independent Director (Age 68)
  • H. Lawrence Remmel Esq., Independent Director (Age 63)
  • Richard I. Steinhart CPA, Independent Director (Age 59)
  • Gregory L. Weaver, Independent Director (Age 61)

Who owns Atossa Genetics stock?

Atossa Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include EMPERY ASSET MANAGEMENT, LP (9.01%). Company insiders that own Atossa Genetics stock include H Lawrence Remmel, Kyle Guse, Shu-Chih Chen and Steven C Quay. View Institutional Ownership Trends for Atossa Genetics.

How do I buy Atossa Genetics stock?

Shares of Atossa Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of Atossa Genetics stock can currently be purchased for approximately $0.36.

How big of a company is Atossa Genetics?

Atossa Genetics has a market capitalization of $9.55 million. The company earns $-6,360,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. Atossa Genetics employs 6 workers across the globe.

How can I contact Atossa Genetics?

Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]


MarketBeat Community Rating for Atossa Genetics (ATOS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Atossa Genetics (NASDAQ:ATOS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Atossa Genetics (NASDAQ:ATOS)

Price Target History for Atossa Genetics (NASDAQ:ATOS)

Analysts' Ratings History for Atossa Genetics (NASDAQ:ATOS)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Atossa Genetics (NASDAQ:ATOS)

Earnings by Quarter for Atossa Genetics (NASDAQ:ATOS)

Earnings History by Quarter for Atossa Genetics (NASDAQ ATOS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
8/14/2017Q2 2017($0.44)($0.64)ViewN/AView Earnings Details
11/14/2016Q316($1.28)$0.07ViewN/AView Earnings Details
8/12/2016Q2($0.07)($0.05)ViewN/AView Earnings Details
5/5/2016Q116($0.07)ViewN/AView Earnings Details
11/12/2015Q315($0.11)($0.15)$2.80 million$0.77 millionViewListenView Earnings Details
8/6/2015Q215($0.12)($0.11)$2.05 million$2.69 millionViewN/AView Earnings Details
5/13/2015Q1($0.11)($0.13)$1.00 million$1.87 millionViewListenView Earnings Details
3/30/2015Q4 2014($0.11)($0.24)$0.10 million$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.13)$76.60 million$3.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.11)($0.10)$1.93 million$0.02 millionViewN/AView Earnings Details
3/27/2014Q4 2013($0.20)($0.15)$0.02 million$0.05 millionViewN/AView Earnings Details
11/12/2013($0.15)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.17)$0.28 million$0.33 millionViewN/AView Earnings Details
5/15/2013Q113($0.11)($0.14)$0.52 million$0.18 millionViewN/AView Earnings Details
12/20/2012Q312($0.10)$0.10 million$0.11 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Atossa Genetics (NASDAQ:ATOS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Atossa Genetics (NASDAQ:ATOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Atossa Genetics (NASDAQ ATOS)

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 7.00%
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)

Insider Trades by Quarter for Atossa Genetics (NASDAQ ATOS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Kyle GuseCFOBuy10,000$0.34$3,400.00View SEC Filing  
4/17/2017H. Lawrence RemmelDirectorBuy2,500$0.63$1,575.00View SEC Filing  
4/1/2016H. Lawrence RemmelDirectorBuy1,500$0.33$495.00View SEC Filing  
3/9/2016Steven C QuayCEOBuy15,000$0.37$5,550.00View SEC Filing  
2/16/2016Shu-Chih ChenDirectorBuy15,000$0.53$7,950.00View SEC Filing  
1/19/2016Steven C QuayCEOBuy50,000$0.20$10,000.00View SEC Filing  
6/12/2015H. Lawrence RemmelDirectorBuy5,400$1.30$7,020.00View SEC Filing  
11/21/2013Gregory L WeaverDirectorBuy10,000$2.58$25,800.00View SEC Filing  
10/1/2013Steven C QuayCEOSell7,265$5.66$41,119.90View SEC Filing  
1/8/2013H. Lawrence RemmelDirectorBuy4,000$4.12$16,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Atossa Genetics (NASDAQ ATOS)

Source:
DateHeadline
Atossa Genetics Inc. Forecasted to Earn FY2017 Earnings of ($0.84) Per Share (ATOS)Atossa Genetics Inc. Forecasted to Earn FY2017 Earnings of ($0.84) Per Share (ATOS)
www.americanbankingnews.com - November 17 at 9:44 PM
Atossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company UpdateAtossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update
finance.yahoo.com - November 14 at 4:38 PM
BRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filingBRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filing
www.reuters.com - November 9 at 5:23 PM
Atossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and PatientsAtossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and Patients
finance.yahoo.com - November 6 at 3:50 PM
Atossa Genetics Inc. (ATOS) Set to Announce Earnings on MondayAtossa Genetics Inc. (ATOS) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
BRIEF-L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26BRIEF-L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
www.reuters.com - November 3 at 9:34 PM
"Economy Still Growing Strong?""Economy Still Growing Strong?"
finance.yahoo.com - October 31 at 5:21 PM
Atossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment OptionAtossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment Option
finance.yahoo.com - October 30 at 5:12 PM
Atossa Genetics (ATOS) Pricing of 11.5M Public Offering of Common Stock at $0.44/ShareAtossa Genetics (ATOS) Pricing of 11.5M Public Offering of Common Stock at $0.44/Share
www.streetinsider.com - October 27 at 11:22 PM
Atossa Genetics (ATOS) Presents On Preliminary Oral Endoixifen Phase 1 Results - SlideshowAtossa Genetics (ATOS) Presents On Preliminary Oral Endoixifen Phase 1 Results - Slideshow
seekingalpha.com - October 27 at 11:22 PM
Atossa Genetics Announces Pricing of $5.1 Million Public Offering of Common StockAtossa Genetics Announces Pricing of $5.1 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 10:04 AM
Atossa Genetics Inc (ATOS) Tumbles After Stock Offering Prices at Deep DiscountAtossa Genetics Inc (ATOS) Tumbles After Stock Offering Prices at Deep Discount
finance.yahoo.com - October 26 at 10:04 AM
Atossa Genetics Announces Proposed Public Offering of Common StockAtossa Genetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 25 at 10:23 PM
Imminent FDA Approval and Lucrative Business Model Indicate Big Near-Term Upside For BTCYImminent FDA Approval and Lucrative Business Model Indicate Big Near-Term Upside For BTCY
finance.yahoo.com - October 25 at 5:20 PM
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Oral EndoxifenAtossa Genetics Announces Preliminary Results from Phase 1 Study of Oral Endoxifen
finance.yahoo.com - October 25 at 5:20 PM
‘Sell the News’ Action Is Taking Atossa Genetics Inc (ATOS) Shares Down‘Sell the News’ Action Is Taking Atossa Genetics Inc (ATOS) Shares Down
finance.yahoo.com - October 25 at 5:20 PM
Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Oral Endoxifen Wednesday, October 25, 2017 at 10 am EDTAtossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Oral Endoxifen Wednesday, October 25, 2017 at 10 am EDT
finance.yahoo.com - October 23 at 3:31 PM
Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter TechnologyAtossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter Technology
www.nasdaq.com - October 16 at 10:02 PM
Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter TechnologyAtossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter Technology
finance.yahoo.com - October 16 at 5:00 PM
Atossa Genetics (ATOS) Announces CAR-T Program in Breast CancerAtossa Genetics (ATOS) Announces CAR-T Program in Breast Cancer
finance.yahoo.com - October 9 at 5:05 PM
Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast CancerAtossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer
www.nasdaq.com - October 2 at 9:08 PM
Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017
finance.yahoo.com - October 2 at 4:04 PM
Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017 - GlobeNewswire (press release)Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017 - GlobeNewswire (press release)
globenewswire.com - September 30 at 11:58 PM
Atossa Genetics Inc. (ATOS) Short Interest UpdateAtossa Genetics Inc. (ATOS) Short Interest Update
www.americanbankingnews.com - September 30 at 3:26 AM
BRIEF-Atossa Genetics files for mixed shelf of upto $50 millionBRIEF-Atossa Genetics files for mixed shelf of upto $50 million
www.reuters.com - September 22 at 11:11 PM
Atossa Genetics, Endoxifen Phase I Results and Pipeline ReviewAtossa Genetics, Endoxifen Phase I Results and Pipeline Review
finance.yahoo.com - September 19 at 4:08 PM
Atossa Genetics (ATOS) On Preliminary Topical Endoxifen Phase 1 Results - ConferenceAtossa Genetics (ATOS) On Preliminary Topical Endoxifen Phase 1 Results - Conference
seekingalpha.com - September 15 at 4:31 PM
Atossa Genetics Announces Preliminary Results From Phase 1 Study Of Topical EndoxifenAtossa Genetics Announces Preliminary Results From Phase 1 Study Of Topical Endoxifen
www.thestreet.com - September 14 at 9:50 PM
BRIEF-Atossa Genetics announces preliminary results from Phase 1 study of topical EndoxifenBRIEF-Atossa Genetics announces preliminary results from Phase 1 study of topical Endoxifen
www.reuters.com - September 14 at 9:50 PM
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Topical EndoxifenAtossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen
finance.yahoo.com - September 14 at 4:46 PM
Todays Research Reports on Stocks to Watch: Atossa Genetics and Forward PharmaToday's Research Reports on Stocks to Watch: Atossa Genetics and Forward Pharma
finance.yahoo.com - September 13 at 5:22 PM
Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDTAtossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT
finance.yahoo.com - September 11 at 4:14 PM
"Meeting Or Exceeding Expectations""Meeting Or Exceeding Expectations"
finance.yahoo.com - August 31 at 4:02 PM
Atossa Genetics Inc. (ATOS) Issues Quarterly  Earnings ResultsAtossa Genetics Inc. (ATOS) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
Atossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company UpdateAtossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update
finance.yahoo.com - August 14 at 4:36 PM
Short Interest in Atossa Genetics Inc. (NASDAQ:ATOS) Expands By 58.1%Short Interest in Atossa Genetics Inc. (NASDAQ:ATOS) Expands By 58.1%
www.americanbankingnews.com - August 13 at 1:46 AM
Atossa Genetics Inc. (NASDAQ:ATOS) to Release Earnings on ThursdayAtossa Genetics Inc. (NASDAQ:ATOS) to Release Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:10 AM
Vista Partners Publishes July 2017 Macroeconomic & Investment NewsletterVista Partners Publishes July 2017 Macroeconomic & Investment Newsletter
finance.yahoo.com - July 27 at 3:54 PM
Atossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 StudyAtossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study
finance.yahoo.com - July 25 at 4:02 PM
BRIEF-Atossa Genetics qtrly loss per share $0.45BRIEF-Atossa Genetics qtrly loss per share $0.45
www.reuters.com - May 11 at 9:08 PM
Atossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation StudyAtossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
www.streetinsider.com - May 11 at 1:53 AM
BRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 studyBRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study
www.reuters.com - May 9 at 8:44 PM
BRIEF-Atossa receives positive interim review from safety committee in Endoxifen studyBRIEF-Atossa receives positive interim review from safety committee in Endoxifen study
www.reuters.com - April 21 at 8:47 PM
Atossa Genetics, Inc. Prices $4,000,000 Public OfferingAtossa Genetics, Inc. Prices $4,000,000 Public Offering
us.rd.yahoo.com - March 29 at 3:54 PM
3:48 am Atossa Genetics prices $4 mln public offering consisting of units, common stock and warrants3:48 am Atossa Genetics prices $4 mln public offering consisting of units, common stock and warrants
us.rd.yahoo.com - March 29 at 3:54 PM
Seattle breast cancer company stock plummets as it seeks funding to continue operationsSeattle breast cancer company stock plummets as it seeks funding to continue operations
www.bizjournals.com - March 29 at 3:54 PM
Atossa Genetics (ATOS) Confirms Pricing of $4M Public OfferingAtossa Genetics (ATOS) Confirms Pricing of $4M Public Offering
www.streetinsider.com - March 29 at 12:53 PM
BRIEF-Atossa Genetics prices $4 mln public offeringBRIEF-Atossa Genetics prices $4 mln public offering
www.reuters.com - March 29 at 12:53 PM
BRIEF-Atossa Genetics files for public offering of up to 4 mln unitsBRIEF-Atossa Genetics files for public offering of up to 4 mln units
www.reuters.com - March 23 at 4:08 PM
ATOSSA GENETICS INC Files SEC form 10-K/A, Annual ReportATOSSA GENETICS INC Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 21 at 12:32 PM

Social Media

Financials

Chart

Atossa Genetics (NASDAQ ATOS) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.